Gastrointestinal stromal tumors (GISTs) are a rare type of tumor that forms in the digestive tract, most commonly in the stomach or small intestine. These tumors develop from specialized cells called interstitial cells of Cajal (ICCs), which regulate the movement of food through the digestive system.

Although GISTs are classified as soft tissue sarcomas, they vary in behavior. Some remain benign (non-cancerous), while others can become malignant (cancerous) and spread to other organs.

Causes and Risk Factors of GISTs

The exact cause of GISTs is not always known, but research has linked them to genetic mutations in the KIT or PDGFRA genes. These mutations lead to uncontrolled cell growth, resulting in tumor formation.

Some key risk factors include:

✔ Age – Most GISTs are diagnosed in people over 40 years old, with the highest risk after 60.
✔ Genetic Syndromes – Some individuals inherit genetic conditions, such as Neurofibromatosis type 1 (NF1), which increases the risk of GISTs.
✔ Gender – GISTs affect both men and women, though studies suggest a slight predominance in males.

Common Symptoms of GISTs

GISTs do not always cause symptoms, especially when small. However, as the tumor grows, it may lead to:

✔ Abdominal pain or discomfort
✔ Nausea and vomiting
✔ Loss of appetite and weight loss
✔ Gastrointestinal bleeding (vomiting blood or passing black, tarry stools)
✔ Fatigue due to anemia

If any of these symptoms persist, medical evaluation is essential for early detection.

How Are GISTs Diagnosed?

Doctors use various tests to diagnose GISTs, including:

✔ Imaging Tests – CT scans, MRIs, and endoscopy help locate the tumor.
✔ Biopsy – A small sample of tumor tissue is examined for cancerous cells.
✔ Molecular Testing – Identifies KIT or PDGFRA gene mutations, helping guide treatment options.

Treatment Options for GISTs

Treatment depends on the size, location, and stage of the tumor:

1. Surgery

✔ Surgical removal is the primary treatment for localized GISTs.
✔ In early-stage cases, surgery alone may be curative.

2. Targeted Therapy (Tyrosine Kinase Inhibitors - TKIs)

✔ Imatinib (Gleevec) – A first-line treatment that blocks abnormal cell growth.
✔ Sunitinib (Sutent) & Regorafenib (Stivarga) – Used when GISTs are resistant to Imatinib.

3. Radiation & Chemotherapy

✔ Rarely used since GISTs do not respond well to traditional chemotherapy.
✔ May be considered in advanced cases when surgery is not possible.

Prognosis and Survival Rates

✔ Early detection improves outcomes, with a 5-year survival rate of over 80% for localized GISTs.
✔ Advanced or metastatic GISTs have lower survival rates, but targeted therapy has significantly improved long-term management.

Conclusion

Gastrointestinal stromal tumors (GISTs) are rare but treatable with early diagnosis and targeted therapies. If you experience persistent digestive issues, consult a doctor for proper evaluation. With advancements in medical treatment, many patients with GISTs can live long and fulfilling lives.